Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|December 17, 2009
Lamivudine for the treatment of HIVPrincy N Kumar, Parul Patel
AIDS Reviews|May 26, 2012
Contemporary role of nevirapine in HIV treatmentLaura O Coster, Princy N Kumar
Infectious Disease Clinics of North America|May 30, 2013
Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipientsJennifer Primeggia, Joseph G Timpone, Princy N Kumar
Journal for Immunotherapy of Cancer|May 22, 2020
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapyMichael T Serzan, Princy N Kumar, Michael B Atkins
The Annals of Otology, Rhinology, and Laryngology|December 18, 2018
Intralesional Cidofovir for Treatment of Acyclovir-Resistant Laryngeal Herpes Manifesting as Supraglottic MassCharles Q Yang, Anisha Mathur, Princy N Kumar, et al.
Current Medical Research and Opinion|July 22, 2023
Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claimsJenny Tse, Girish Prajapati, Xiaohui Zhao, et al.
Current Medical Research and Opinion|June 19, 2023
Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claimsXiaohui Zhao, Girish Prajapati, Jenny Tse, et al.
The AIDS Reader|July 1, 2008
Serious infection from Staphylococcus aureus in 2 HIV-infected patients receiving fusion inhibitor therapyElizabeth M Gaughan, Michelle L Ritter, Princy N Kumar, et al.
Reviews in Cardiovascular Medicine|July 23, 2014
Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarctionShrinivas Hebsur, Erik Vakil, William J Oetgen, et al.
Pharmacoeconomics|February 3, 2021
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United StatesAnita J Brogan, Sandra E Talbird, Ashley E Davis, et al.
Pageof 5